JP6472608B2 - N−アセチルグルコサミン糖鎖基含有化合物、薬剤輸送用キャリアー化合物、製剤、及び、薬剤輸送システム - Google Patents
N−アセチルグルコサミン糖鎖基含有化合物、薬剤輸送用キャリアー化合物、製剤、及び、薬剤輸送システム Download PDFInfo
- Publication number
- JP6472608B2 JP6472608B2 JP2014104811A JP2014104811A JP6472608B2 JP 6472608 B2 JP6472608 B2 JP 6472608B2 JP 2014104811 A JP2014104811 A JP 2014104811A JP 2014104811 A JP2014104811 A JP 2014104811A JP 6472608 B2 JP6472608 B2 JP 6472608B2
- Authority
- JP
- Japan
- Prior art keywords
- sugar chain
- chain group
- acetylglucosamine sugar
- drug
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims description 138
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 title claims description 131
- 229950006780 n-acetylglucosamine Drugs 0.000 title claims description 122
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 title claims description 119
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 title claims description 119
- 239000003814 drug Substances 0.000 title claims description 82
- 229940079593 drug Drugs 0.000 title claims description 69
- 238000002360 preparation method Methods 0.000 title claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 30
- 239000002245 particle Substances 0.000 claims description 27
- 238000012377 drug delivery Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 16
- 239000000178 monomer Substances 0.000 claims description 16
- 239000002872 contrast media Substances 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 claims description 8
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- -1 biotin compound Chemical class 0.000 claims description 5
- 230000000379 polymerizing effect Effects 0.000 claims description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 4
- BVWUEIUNONATML-UHFFFAOYSA-N n-benzylethenamine Chemical compound C=CNCC1=CC=CC=C1 BVWUEIUNONATML-UHFFFAOYSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 28
- 230000000052 comparative effect Effects 0.000 description 22
- 102000013127 Vimentin Human genes 0.000 description 19
- 108010065472 Vimentin Proteins 0.000 description 19
- 210000005048 vimentin Anatomy 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 230000027455 binding Effects 0.000 description 13
- QLTSDROPCWIKKY-PMCTYKHCSA-N beta-D-glucosaminyl-(1->4)-beta-D-glucosamine Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O1 QLTSDROPCWIKKY-PMCTYKHCSA-N 0.000 description 9
- 102100036912 Desmin Human genes 0.000 description 8
- 108010044052 Desmin Proteins 0.000 description 8
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 8
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 7
- 210000005045 desmin Anatomy 0.000 description 7
- 229910052737 gold Inorganic materials 0.000 description 7
- 239000010931 gold Substances 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 206010016654 Fibrosis Diseases 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 230000003176 fibrotic effect Effects 0.000 description 5
- 125000001165 hydrophobic group Chemical group 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 229940093817 Convertase inhibitor Drugs 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 229920000747 poly(lactic acid) Polymers 0.000 description 4
- 239000004626 polylactic acid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical class CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012986 chain transfer agent Substances 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 230000002966 stenotic effect Effects 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- FYXAVEIRUNEOSG-UHFFFAOYSA-N 4-benzyl-5-ethenylisoindole-1,3-dione Chemical compound C=CC1=CC=C2C(=O)NC(=O)C2=C1CC1=CC=CC=C1 FYXAVEIRUNEOSG-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical group O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 150000002251 gadolinium compounds Chemical class 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000004683 skeletal myoblast Anatomy 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000009092 tissue dysfunction Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F12/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
- C08F12/02—Monomers containing only one unsaturated aliphatic radical
- C08F12/04—Monomers containing only one unsaturated aliphatic radical containing one ring
- C08F12/14—Monomers containing only one unsaturated aliphatic radical containing one ring substituted by hetero atoms or groups containing heteroatoms
- C08F12/26—Nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F12/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
- C08F12/02—Monomers containing only one unsaturated aliphatic radical
- C08F12/32—Monomers containing only one unsaturated aliphatic radical containing two or more rings
Description
本発明の薬剤輸送用キャリアー化合物は、本発明のN−アセチルグルコサミン糖鎖基含有化合物からなるものである。本発明の薬剤輸送用キャリアー化合物は、前記N−アセチルグルコサミン基含有化合物のみから構成されてもよいが、薬剤輸送に用いられる担体等の他の材料、例えば、コロイド状粒子の表面に前記N−アセチルグルコサミン糖鎖基含有化合物を結合させたものであってもよい。コロイド状粒子としては、例えば金、白金、銀、磁性体、セラミックなどの金属又は無機粒子、ポリエチレングリコール、ポリスチレン、アクリル系樹脂、ポリ乳酸、ポリカプロラクトン、ポリヒドロキシアルカノエート、ポリグリコール酸、変性ポリビニルアルコール、カゼイン、変性澱粉及びセルロース、プロテインなどの合成又は天然物由来樹脂粒子、リポソームなどが挙げられる。このコロイド状粒子の表面にN−アセチルグルコサミン糖鎖基含有化合物を結合させる方法は特に限定されない。例えば、コロイド状粒子が金粒子の場合、N−アセチルグルコサミン糖鎖基含有化合物にチオール基を導入し、金コロイド表面への共有結合を行うことにより結合させることができる。また、ポリ乳酸の場合、N−アセチルグルコサミン基含有化合物を溶解させた溶液をポリ乳酸と混合し、ポリ乳酸粒子の表面にN−アセチルグルコサミン糖鎖基含有化合物をコーティングすることにより結合させることができる。さらにリポソームの場合は、N−アセチルグルコサミン糖鎖基含有化合物にアルキル基を導入したものをリポソーム表面にコーティングすることにより結合させることができる。
本発明の製剤は、前記薬剤輸送用キャリアー化合物が、治療剤、蛍光剤および造影剤のうち少なくとも1種の薬剤を担持し、かつ、前記N−アセチルグルコサミン糖鎖基が表面に露出していることを特徴とするものである。また、本発明の他の製剤は、前記薬剤輸送用キャリアー化合物がN−アセチルグルコサミン糖鎖基が表面に露出しているコロイド状粒子であって、前記コロイド状粒子中に、治療剤、蛍光剤および造影剤のうち少なくとも1種の薬剤が含有されていることを特徴とするものである。これらの本発明の製剤は投与されると、ビメンチンやデスミン等のN−アセチルグルコサミン糖鎖認識タンパク質を露出している細胞・部位に血液循環により到達する。すると薬剤輸送用キャリアー化合物のN−アセチルグルコサミン糖鎖基と、N−アセチルグルコサミン糖鎖認識タンパク質とが相互作用して引き寄せあい、この細胞に付着したり侵入したりする。その後、前記薬剤が製剤中から滲出して放出され、細胞に吸収され、蛍光させたり造影させたり薬効を発現するものである。
本発明の薬剤輸送システムは、蛍光剤、造影剤および治療剤のうち少なくとも1種の薬剤の表面に、本発明の化合物を結合させて、表面に露出したN−アセチルグルコサミン糖鎖基によって、前記薬剤を患部領域に誘導することを特徴とするものである。また、本発明の他の薬剤輸送システムは、表面に本発明の化合物を結合させたコロイド状粒子中に治療剤、蛍光剤および造影剤のうち少なくとも1種の薬剤を含有させ、表面に露出したN−アセチルグルコサミン糖鎖基によって前記コロイド状粒子中の前記薬剤を目的の患部領域に誘導することを特徴とするものである。
キトビオース(0.5g)をメタノール(20mL)に溶解して、1.425gのヨウ素を添加した。4%KOHをヨウ素の茶色が消えるまで滴下して加えた。その後、ジエチルエーテルで再結晶させた後、結晶物を水に溶解してイオン交換樹脂(アンバーライトIR−120)でキトビオン酸を精製した。ビニルベンジルアミンにWSC(水溶性カルボジイミド)を用いてキトビオン酸を縮合した。作製されたモノマーはクロロホルムで沈殿精製した。その後、沈殿物を水に溶解して凍結乾燥を行った。
上記で得たモノマー 0.185mmolに、0.00185mmol 3−メルカプトプロピオン酸(MPA)、及び、終濃度が0.5%になる量でアゾビスイソブチロニトリル(AIBN)を混合し、500μLのジメチルスルホキシド(DMSO)に溶解させた。この溶液を65℃のオイルバス中で18時間インキュベーションを行い重合した。18時間後、水に溶解させ一昼夜透析を行った。透析後、凍結乾燥を行った。
上記で得たモノマー 0.185mmolに、0.0009mmol MPA、及び、終濃度が0.5%になる量でAIBNを混合し、500μLのDMSOに溶解させた。この溶液を65℃のオイルバス中で18時間インキュベーションを行い重合した。18時間後、水に溶解させ一昼夜透析を行った。透析後、凍結乾燥を行った。
上記で得たモノマー 0.185mmolに、0.00037mmol MPA、及び、終濃度が0.5%になる量でAIBNを混合し、500μLのDMSOに溶解させた。この溶液を65℃のオイルバス中で18時間インキュベーションを行い重合した。18時間後、水に溶解させ一昼夜透析を行った。透析後、凍結乾燥を行った。
上記で得たモノマー 0.185mmolに、0.000185mmol MPA、及び、終濃度が0.5%になる量でAIBNを混合し、500μLのDMSOに溶解させた。この溶液を65℃のオイルバス中で18時間インキュベーションを行い重合した。18時間後、水に溶解させ一昼夜透析を行った。透析後、凍結乾燥を行った。
上記で得たモノマー 0.185mmolに、終濃度が0.5%になる量でAIBNを混合し、500μLのDMSOに溶解させた。この溶液を65℃のオイルバス中で18時間インキュベーションを行い重合した。18時間後、水に溶解させ一昼夜透析を行った。透析後、凍結乾燥を行った
ビメンチンのN−アセチルグルコサミン結合ドメインの組み替えタンパク質をセンサーチップに固定化して、GEヘルスケア社製BIACORE−Jを用いて、N−アセチルグルコサミン糖鎖基含有化合物のビメンチンへの相互作用を表面プラズモン共鳴解析によって検討した。得られたセンサーグラムから相互作用の程度を、センサーグラムを観察し、目視により、センサーグラムの最大の値を比較して相対的に判断した。
N−アセチルグルコサミン糖鎖基含有化合物の5種類の濃度系列(0.5μg/ml、1μg/ml、2.5μg/ml、5μg/ml、10μg/mlの5種類)を用意して、金表面に固定化したビメンチンと用意したN−アセチルグルコサミン糖鎖基含有化合物との結合(分子間相互作用)をGEヘルスケア社製BIACORE−Jで検討した。各濃度のセンサーグラムの結果から、N−アセチルグルコサミン糖鎖基含有化合物の解離定数を算出した。比較例2、比較例3、実施例1および比較例4のN−アセチルグルコサミン糖鎖含有化合物のセンサーグラムの結果をそれぞれ、図1〜4に示す(比較例3については、0.5μg/mlは未測定)。縦軸はレゾナンスユニットを、横軸は時間(秒)を表す。これらの図は、各濃度の化合物のビメンチンに対する反応性を示したものである。高濃度になるにつれて反応性が上昇している。N−アセチルグルコサミン糖鎖基含有化合物をビメンチンに反応させてから120秒(比較例は60秒)まではビメンチンとの結合を示し120秒(比較例は60秒)以降は、ビメンチンからのN−アセチルグルコサミン糖鎖基含有化合物の解離を示している。これらの反応経過から解離定数を算出した。尚、比較例2については、0.5μg/mlはほとんど変化せず、解離定数の計算から外した。
5×105cells/mLのHeLa細胞懸濁液500μLにFITCラベルしたN−アセチルグルコサミン糖鎖基含有化合物(FITC−PV−GlcNAc)を4μg/mLで反応させた。反応は、4℃で30分行った。その後、遠心を行いPBSに再懸濁して、その細胞染色をフローサイトメーター(GUAVA easyCyte、ミリポア社製)でフローサイトメトリーを行い、FITC−PV−GlcNAcによるHeLa細胞の染色を検討した。比較例1、比較例2、比較例3、実施例1および比較例4のN−アセチルグルコサミン糖鎖含有化合物のフローサイトメトリーの結果をそれぞれ、図5〜9に示す。縦軸は細胞数、横軸は蛍光強度を表す。中塗りつぶしのヒストグラムは、ネガティブコントロールとしてFITC−PV−MAを作用させたものであり、中抜けのヒストグラムはFITC−PV−GlcNAcに反応したHeLa細胞集団を示している。
高速GPC装置(東ソー社製、HLC−8220GPC)を用いて、次の条件で各材料の重量平均分子量を測定した。カラムは、TSKgel G6000PWxL−CP+G5000PWxL−CP+3000PWxL−CPを用いて溶離液は、200mM 硝酸ナトリウム/アセトニトリル=80/20で行った。流量は1mL/min、検出器はRI検出器、カラム温度は40℃で行った。分子量の標準曲線はプルランで実施した。
Claims (8)
- N−アセチルグルコサミン糖鎖基含有化合物の製造方法であって、
前記N−アセチルグルコサミン糖鎖基含有化合物が、重量平均分子量が15,000〜30,000の範囲であり、N−アセチルグルコサミン糖鎖基を1分子当たり27〜50個有し、末端に3−メルカプトプロピオン酸が結合されたN−アセチルグルコサミン糖鎖基含有化合物であり、
ビニルベンジルアミンに水溶性カルボジイミドを用いてキトビオン酸を縮合して作製したモノマーを、3−メルカルトプロピオン酸及びアゾビスイソブチロニトリルと混合して重合させることを特徴とするN−アセチルグルコサミン糖鎖基含有化合物の製造方法。 - 前記N−アセチルグルコサミン糖鎖基含有化合物がビオチン化合物であることを特徴とする請求項1記載のN−アセチルグルコサミン糖鎖基含有化合物の製造方法。
- 薬剤輸送用キャリアー化合物の製造方法であって、
前記薬剤輸送用キャリアー化合物が、N−アセチルグルコサミン糖鎖基含有化合物からなる薬剤輸送用キャリアー化合物であり、
前記N−アセチルグルコサミン糖鎖基含有化合物を、請求項1または2記載のN−アセチルグルコサミン糖鎖基含有化合物の製造方法で製造することを特徴とする薬剤輸送用キャリアー化合物の製造方法。 - 前記薬剤輸送用キャリアー化合物が、前記N−アセチルグルコサミン糖鎖基が表面に露出しているコロイド状粒子であることを特徴とする請求項3記載の薬剤輸送用キャリアー化合物の製造方法。
- 製剤の製造方法であって、
前記製剤が、薬剤輸送用キャリアー化合物が、治療剤、蛍光剤および造影剤のうち少なくとも1種の薬剤を担持し、かつ、N−アセチルグルコサミン糖鎖基が表面に露出している製剤であり、
前記薬剤輸送用キャリアー化合物を請求項3記載の薬剤輸送用キャリアー化合物の製造方法で製造することを特徴とする製剤の製造方法。 - 製剤の製造方法であって、
前記製剤が、N−アセチルグルコサミン糖鎖基が表面に露出しているコロイド状粒子である薬剤輸送用キャリアー化合物の前記コロイド状粒子中に、治療剤、蛍光剤および造影剤のうち少なくとも1種の薬剤を含有する製剤であり、
前記薬剤輸送用キャリアー化合物を、請求項3記載の薬剤輸送用キャリアー化合物の製造方法で製造することを特徴とする製剤の製造方法。 - 治療剤、蛍光剤および造影剤のうち少なくとも1種の薬剤の表面に請求項1または2記載のN−アセチルグルコサミン糖鎖基含有化合物の製造方法で製造したN−アセチルグルコサミン糖鎖基含有化合物を結合させて、表面に露出したN−アセチルグルコサミン糖鎖基によって前記薬剤を目的の患部領域に誘導することを特徴とする薬剤輸送システム。
- 表面に請求項1または2記載のN−アセチルグルコサミン糖鎖基含有化合物の製造方法で製造したN−アセチルグルコサミン糖鎖基含有化合物を結合させたコロイド状粒子中に治療剤、蛍光剤および造影剤のうち少なくとも1種の薬剤を含有させ、表面に露出したN−アセチルグルコサミン糖鎖基によって前記コロイド状粒子中の前記薬剤を目的の患部領域に誘導することを特徴とする薬剤輸送システム。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014104811A JP6472608B2 (ja) | 2014-05-21 | 2014-05-21 | N−アセチルグルコサミン糖鎖基含有化合物、薬剤輸送用キャリアー化合物、製剤、及び、薬剤輸送システム |
CN201580026100.4A CN106459259B (zh) | 2014-05-21 | 2015-05-19 | 含n-乙酰葡糖胺糖链基化合物、药剂输送用载体化合物、制剂、及药剂输送系统 |
KR1020167035868A KR102170249B1 (ko) | 2014-05-21 | 2015-05-19 | N-아세틸글루코사민 당쇄기 함유 화합물, 약제 수송용 캐리어 화합물, 제제, 및 약제 수송 시스템 |
PCT/JP2015/064344 WO2015178380A1 (ja) | 2014-05-21 | 2015-05-19 | N-アセチルグルコサミン糖鎖基含有化合物、薬剤輸送用キャリアー化合物、製剤、及び、薬剤輸送システム |
US15/312,507 US10471158B2 (en) | 2014-05-21 | 2015-05-19 | N-acetylglucosamine sugar chain group-containing compound, carrier compound for drug delivery, drug preparation, and drug delivery system |
EP15796230.9A EP3147300B1 (en) | 2014-05-21 | 2015-05-19 | N-acetylglucosamine sugar chain group-containing polymer, carrier compound for drug delivery, drug preparation, and drug delivery system |
TW104116215A TWI723951B (zh) | 2014-05-21 | 2015-05-21 | 含n-乙醯葡萄胺糖鏈基之化合物、藥劑輸送用載體化合物、製劑及藥劑輸送系統 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014104811A JP6472608B2 (ja) | 2014-05-21 | 2014-05-21 | N−アセチルグルコサミン糖鎖基含有化合物、薬剤輸送用キャリアー化合物、製剤、及び、薬剤輸送システム |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015218314A JP2015218314A (ja) | 2015-12-07 |
JP6472608B2 true JP6472608B2 (ja) | 2019-02-20 |
Family
ID=54554048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014104811A Active JP6472608B2 (ja) | 2014-05-21 | 2014-05-21 | N−アセチルグルコサミン糖鎖基含有化合物、薬剤輸送用キャリアー化合物、製剤、及び、薬剤輸送システム |
Country Status (7)
Country | Link |
---|---|
US (1) | US10471158B2 (ja) |
EP (1) | EP3147300B1 (ja) |
JP (1) | JP6472608B2 (ja) |
KR (1) | KR102170249B1 (ja) |
CN (1) | CN106459259B (ja) |
TW (1) | TWI723951B (ja) |
WO (1) | WO2015178380A1 (ja) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2986173B2 (ja) * | 1989-04-20 | 1999-12-06 | 三井化学株式会社 | N―アセチルキトオリゴ糖鎖を有するスチレン誘導体及びその製造方法 |
US5206318A (en) * | 1989-04-20 | 1993-04-27 | Mitsui Toatsu Chemicals, Inc. | Styrene derivatives having N-acetylchito-oligosaccharide chains and method for the same |
JP3200607B2 (ja) | 1995-03-17 | 2001-08-20 | 財団法人神奈川科学技術アカデミー | 細胞診断用標識剤及びそれを用いた細胞診断システム |
EP0866802A1 (en) * | 1995-11-21 | 1998-09-30 | Novartis AG | Multivalent polymers, processes for their preparation, and their use for preparing biologically active compounds. |
WO2003011879A1 (en) * | 2001-08-01 | 2003-02-13 | Neose Technologies, Inc. | Neutral glycosphingolipids and glycosyl-sphingosines and methods for isolating the same |
GB0217136D0 (en) | 2002-07-24 | 2002-09-04 | Renovo Ltd | Wound healing & treatment of fibrosis |
JP2007001923A (ja) | 2005-06-23 | 2007-01-11 | Shinshu Univ | N−アセチルグルコサミン糖鎖認識タンパク質 |
JP2009046413A (ja) | 2007-08-17 | 2009-03-05 | Shinshu Univ | N−アセチルグルコサミン糖鎖認識タンパク質 |
CN103534276B (zh) * | 2011-03-10 | 2016-03-02 | 株式会社糖锁工学研究所 | 具有唾液酸糖链的糖肽的制造方法、用于该制造方法的唾液酸糖链加成氨基酸衍生物及该糖肽 |
JP5829871B2 (ja) | 2011-09-16 | 2015-12-09 | 株式会社Ihi | リポソーム薬剤 |
-
2014
- 2014-05-21 JP JP2014104811A patent/JP6472608B2/ja active Active
-
2015
- 2015-05-19 KR KR1020167035868A patent/KR102170249B1/ko active IP Right Grant
- 2015-05-19 EP EP15796230.9A patent/EP3147300B1/en active Active
- 2015-05-19 WO PCT/JP2015/064344 patent/WO2015178380A1/ja active Application Filing
- 2015-05-19 US US15/312,507 patent/US10471158B2/en active Active
- 2015-05-19 CN CN201580026100.4A patent/CN106459259B/zh active Active
- 2015-05-21 TW TW104116215A patent/TWI723951B/zh active
Also Published As
Publication number | Publication date |
---|---|
EP3147300B1 (en) | 2020-06-24 |
KR102170249B1 (ko) | 2020-10-26 |
TWI723951B (zh) | 2021-04-11 |
EP3147300A1 (en) | 2017-03-29 |
JP2015218314A (ja) | 2015-12-07 |
US10471158B2 (en) | 2019-11-12 |
CN106459259B (zh) | 2022-07-15 |
CN106459259A (zh) | 2017-02-22 |
KR20170012369A (ko) | 2017-02-02 |
EP3147300A4 (en) | 2017-12-27 |
TW201620552A (zh) | 2016-06-16 |
WO2015178380A1 (ja) | 2015-11-26 |
US20170095564A1 (en) | 2017-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6155287B2 (ja) | 機能性pla−peg共重合体、そのナノ粒子、その製造、ならびに標的薬物送達およびイメージングのためのその使用 | |
Rajan et al. | Poly-carboxylic acids functionalized chitosan nanocarriers for controlled and targeted anti-cancer drug delivery | |
JP5597396B2 (ja) | 葉酸修飾されたシクロデキストリン化合物、その製造方法、標的指向性薬物送達システム用の薬物送達剤、医薬組成物及び造影剤 | |
JP5914366B2 (ja) | 誘導体化超分岐ポリグリセロール類 | |
JP6246421B2 (ja) | 側鎖にジチオ五員環官能基を有するカーボネートポリマー及びその応用 | |
Zhao et al. | Redox and pH dual sensitive bone targeting nanoparticles to treat breast cancer bone metastases and inhibit bone resorption | |
Deng et al. | Reactive oxygen species (ROS) responsive PEG–PCL nanoparticles with pH-controlled negative-to-positive charge reversal for intracellular delivery of doxorubicin | |
Wu et al. | In vitro drug release and biological evaluation of biomimetic polymeric micelles self-assembled from amphiphilic deoxycholic acid–phosphorylcholine–chitosan conjugate | |
Zhu et al. | Vinblastine-loaded nanoparticles with enhanced tumor-targeting efficiency and decreasing toxicity: developed by one-step molecular imprinting process | |
Li et al. | Smart pH-responsive and high doxorubicin loading nanodiamond for in vivo selective targeting, imaging, and enhancement of anticancer therapy | |
Liu et al. | High-order assembly toward polysaccharide-based complex coacervate nanodroplets capable of targeting cancer cells | |
Chen et al. | Branched polyethyleneimine modified with hyaluronic acid via a PEG spacer for targeted anticancer drug delivery | |
Khoshnood et al. | N doped-carbon quantum dots with ultra-high quantum yield photoluminescent property conjugated with folic acid for targeted drug delivery and bioimaging applications | |
Pan et al. | Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer | |
Atrei et al. | Covalent hyaluronic-based coating of magnetite nanoparticles: Preparation, physicochemical and biological characterization | |
JP6472608B2 (ja) | N−アセチルグルコサミン糖鎖基含有化合物、薬剤輸送用キャリアー化合物、製剤、及び、薬剤輸送システム | |
Zhang et al. | Engineering of biocompatible pH-responsive nanovehicles from acetalated cyclodextrins as effective delivery systems for tumor therapy | |
Li et al. | Effect of protein adsorption on cell uptake and blood clearance of methoxy poly (ethylene glycol)‐poly (caprolactone) nanoparticles | |
Ehsanimehr et al. | Redox and pH‐Responsive NCC/L‐Cysteine/CM‐β‐CD/FA Contains Disulfide Bond‐Bridged as Nanocarriers for Biosafety and Anti‐Tumor Efficacy System | |
Negrete et al. | PDA-Based Glyconanomicelles for Hepatocellular Carcinoma Cells Active Targeting Via Mannose and Asialoglycoprotein Receptors | |
Ke et al. | Inhibition of cancer-associated thrombosis with redox-sensitive paclitaxel/heparin-deoxycholic acid nanoparticles | |
US20180280548A1 (en) | Gas-generating polymer micells and manufacturing method of the same | |
Bandi et al. | Hydrocaffeic acid-chitosan coating of gastric patch provides long-acting mucoadhesive delivery of model chemotherapeutic agent | |
CN115025240B (zh) | 一种蛋白聚糖修饰的纳米粒及其制备和应用 | |
KR20120120712A (ko) | 헤파린-도세탁셀-토로콜산 접합체로 이루어진 표적성이 향상된 수용성 항암제 및 그의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170322 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171010 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171208 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180209 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180724 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181024 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20181101 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190115 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190123 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6472608 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |